Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time?

Ponziani, Francesca Romana; Pompili, Maurizio; Gasbarrini, Antonio

doi:10.1007/s10620-017-4656-1

Cited by 4 publications

(2 citation statements)

References 12 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(9) W 2015 r. ryfaksymina została zatwierdzona przez amerykańską Agencję ds. Żywności i Leków (FDA) do leczenia IBS-D. (10) W celu oceny odpowiedzi u pacjentów z kolejnymi zaostrzeniami wykonano badanie TARGET 3. Zbadano skuteczność ponownego leczenia ryfaksyminą u pacjentów z IBS-D, u których wystąpił objawowy nawrót po początkowym skutecznym leczeniu ryfaksyminą.…”

Section: Stan Wiedzyunclassified

“…U chorych z IBS stosowanie ryfaksyminy przez 2 tygodnie wiązało się ze zmniejszeniem nasilenia łącznych dolegliwości, wzdęcia, bólu brzucha i dyskomfortu oraz poprawą konsystencji stolca w ciągu 4 i 12 tygodni oraz nie zwiększyło ryzyka objawów niepożądanych. (10) Polskie Towarzystwo Gastroenterologii rekomenduje 14-dniową terapię ryfaksyminą α w postaciach: z dominującą biegunką, mieszanej i niesklasyfikowanej, w celu zmniejszenia objawów ogółem, jak również zmniejszenia nasilenia wzdęcia i/lub biegunki. W przypadku pierwszych dwóch nawrotów dolegliwości u pacjentów, którzy odnieśli korzyść z terapii ryfaksyminą α, rekomendujemy powtórne leczenie w takim samym schemacie.…”

Section: Podsumowanieunclassified

See 1 more Smart Citation

Use of Rifaximin in Irritable Bowel Syndrome Treatment

Wróblewski¹,

Zimna²

2021

J Educ Health Sport

View full text Add to dashboard Cite

Introduction and purpose of the work: Irritable Bowel Syndrome (IBS) affects up to 10% of the population. The deterioration in health-related quality of life in IBS patients has been shown to be comparable to, and perhaps even more severe than, other serious chronic organic diseases such as inflammatory bowel disease, diabetes, hypertension, and end-stage renal disease. The aim of the study is to present a new method of IBS treatment.State of knowledge: There are four main types of IBS: Constipation-predominant IBS (IBS-C), Diarrhea-predominant IBS (IBS-D), Fluctuating IBS (IBS-M), and the unclassified form of IBS (IBS-U). Disturbances in entero-brain interactions play a key role in its multifactorial etiopathogenesis. In patients with IBS, quantitative and qualitative disturbances in the composition of the intestinal microbiota can be found. So far, it has not been possible to clearly establish the cause of the disease, so there is no possibility of causal therapy and effective cure. Both non-pharmacological methods and drugs, including rifaximin α, have been used in IBS therapy.Summary: Rifaximin has a positive effect on the symptoms of IBS. In clinical trials conducted in patients with IBS, the use of rifaximin for 2 weeks was associated with a reduction in the severity of joint symptoms, bloating, abdominal pain and discomfort, and an improvement in stool consistency within 4 and 12 weeks, and did not increase the risk of side effects. In the forms: with predominant diarrhea, mixed and unclassified, in order to reduce the overall symptoms as well as reduce the severity of flatulence and / or diarrhea, a 14-day therapy with rifaximin α is recommended.

show abstract

Section: Stan Wiedzyunclassified

Section: Podsumowanieunclassified

Use of Rifaximin in Irritable Bowel Syndrome Treatment

Wróblewski¹,

Zimna²

2021

J Educ Health Sport

View full text Add to dashboard Cite

show abstract

HS-SPME-GC-MS approach for the analysis of volatile salivary metabolites and application in a case study for the indirect assessment of gut microbiota

et al. 2019

View full text Add to dashboard Cite

From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes

Widjaja,

Rietjens

2023

Biomedicines

View full text Add to dashboard Cite

The composition, viability and metabolic functionality of intestinal microbiota play an important role in human health and disease. Studies on intestinal microbiota are often based on fecal samples, because these can be sampled in a non-invasive way, although procedures for sampling, processing and storage vary. This review presents factors to consider when developing an automated protocol for sampling, processing and storing fecal samples: donor inclusion criteria, urine–feces separation in smart toilets, homogenization, aliquoting, usage or type of buffer to dissolve and store fecal material, temperature and time for processing and storage and quality control. The lack of standardization and low-throughput of state-of-the-art fecal collection procedures promote a more automated protocol. Based on this review, an automated protocol is proposed. Fecal samples should be collected and immediately processed under anaerobic conditions at either room temperature (RT) for a maximum of 4 h or at 4 °C for no more than 24 h. Upon homogenization, preferably in the absence of added solvent to allow addition of a buffer of choice at a later stage, aliquots obtained should be stored at either −20 °C for up to a few months or −80 °C for a longer period—up to 2 years. Protocols for quality control should characterize microbial composition and viability as well as metabolic functionality.

show abstract

Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time?

Cited by 4 publications

References 12 publications

Use of Rifaximin in Irritable Bowel Syndrome Treatment

Use of Rifaximin in Irritable Bowel Syndrome Treatment

HS-SPME-GC-MS approach for the analysis of volatile salivary metabolites and application in a case study for the indirect assessment of gut microbiota

From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes

Contact Info

Product

Resources

About